Latest News
Jubilant Therapeutics to present LSD1 and HDAC6 (CoREST) orally administered dual inhibitor Phase 1/2 study results at 68th ASH Annual Meeting
11 November 2026 - Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesday that clinical results from its Phase 1/2 study o...
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
11 November 2026 - Nuvation Bio Inc (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Tuesday that David Hung, MD, founder, president, and chief executive officer of Nuvation Bio, and Philippe Sauvage, ...
Abbisko Therapeutics' PIMJETMI receives US FDA approval to treat tenosynovial giant cell tumour (TGCT)
11 November 2026 - Abbisko Therapeutics Co Ltd (HKEX code: 02256.HK), a China-based biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved PIMJETMI (pimicotinib), a small-molecule colony-stimulatin...
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
10 November 2026 - Preclinical biotechnology company Omniose announced on Tuesday that it has been acquired by biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN).This acquisition brings Omniose's proprietary bioconjugation ...
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
10 November 2026 - Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Tuesday that it has secured a US patent covering the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib for the treatment of hepatocellular carcinom...